Article
Oncology
Yi Li, Xiwen Tong, Lifang Huang, Li Li, Chunyan Wang, Cheng He, Songya Liu, Zhiqiong Wang, Min Xiao, Xia Mao, Donghua Zhang
Summary: A new CLL scoring system was developed, replacing CD5 and CD23 with CD43 and CD180, to differentiate chronic lymphocytic leukemia in Asian patients. The new score showed improved sensitivity and specificity in distinguishing CLL, particularly in atypical CLL cases.
Review
Oncology
Giulia Benintende, Federico Pozzo, Idanna Innocenti, Francesco Autore, Alberto Fresa, Giovanni D'Arena, Valter Gattei, Luca Lurenti
Summary: Measurable residual disease (MRD) refers to the presence of cancer cells that remain after treatment in patients with no clinically detectable disease. It is a highly sensitive parameter that indicates disease burden and predicts survival in these patients.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Giovanni Riva, Vincenzo Nasillo, Anna Maria Ottomano, Giuliano Bergonzini, Ambra Paolini, Fabio Forghieri, Beatrice Lusenti, Patrizia Barozzi, Ivana Lagreca, Stefania Fiorcari, Silvia Martinelli, Rossana Maffei, Roberto Marasca, Leonardo Potenza, Patrizia Comoli, Rossella Manfredini, Enrico Tagliafico, Tommaso Trenti, Mario Luppi
Summary: MRD monitoring plays an increasingly important role in the clinical management of hematologic malignancies, providing valuable information for treatment selection. However, further research is needed to determine the specific prognostic value of MRD in different hematologic settings, as well as its appropriate clinical applications in order to improve standardization and harmonization of MRD monitoring protocols.
Article
Veterinary Sciences
Ga-Won Lee, Min-Hee Kang, Jin-Ha Jeon, Doo-Won Song, Woong-Bin Ro, Heyong-Seok Kim, Hee-Myung Park
Summary: This study suggests that imatinib may be an effective adjunctive therapy with prednisolone and chlorambucil treatment for dogs with treatment-resistant chronic lymphocytic leukemia (CLL).
FRONTIERS IN VETERINARY SCIENCE
(2022)
Article
Oncology
Mohamed E. Salama, Gregory E. Otteson, Jon J. Camp, Jansen N. Seheult, Dragan Jevremovic, David R. Holmes, Horatiu Olteanu, Min Shi
Summary: Flow cytometric immunophenotyping is critical in detecting minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL). In this study, a deep neural network (DNN) approach was evaluated for its performance in detecting CLL MRD, and it was found to have high accuracy and improve workflow efficiency.
Article
Oncology
Luciana Valvano, Fiorella D'Auria, Vitina Grieco, Teodora Statuto, Filomena Nozza, Giuseppe Pietrantuono, Oreste Villani, Giovanni D'Arena, Daniela Lamorte
Summary: This case report describes a rare case of a 50-year-old male patient with concomitant HCL and CLL, using flow cytometry and ddPCR to detect the BRAF V600E mutation, emphasizing the importance of analyzing chronic lymphoproliferative disorders using highly sensitive diagnostic techniques.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pathology
Anya K. Hotinski, Oliver G. Best, Bryone J. Kuss
Summary: Chronic lymphocytic leukaemia (CLL) is a clonally complex disease with high intra-tumoural and inter-patient heterogeneity, requiring accurate prognostic tests. The emergence of new targeted agents in recent years has also created a need for improved predictive tests in therapy.
Article
Oncology
Joerg Hoffmann, Semil Eminovic, Christian Wilhelm, Stefan W. Krause, Andreas Neubauer, Michael C. Thrun, Alfred Ultsch, Cornelia Brendel
Summary: This study found that multiparameter flow cytometry (MPFC) data can predict the outcome of chronic lymphocytic leukemia (CLL) using explainable artificial intelligence (XAI) methods. Specifically, a cell population consisting of CD4+ T cells was found to have higher predictive ability in determining patient outcomes, and its inclusion enhanced the predictive ability of the conventional prognostic score (IPI).
Article
Medicine, General & Internal
Yulia Davydova, Irina Galtseva, Nikolay Kapranov, Ksenia Nikiforova, Olga Aleshina, Yulia Chabaeva, Galina Isinova, Ekaterina Kotova, Andrey Sokolov, Vera Troitskaya, Sergey Kulikov, Elena Parovichnikova
Summary: Measurable residual disease (MRD) is an independent prognostic factor in acute leukemias. Multicolor flow cytometry (MFC) is used to detect MRD and determine the antigen expression profile of residual blast cells. The MRD immunophenotype is associated with relapse-free survival (RFS) and can be an additional prognostic factor for B-cell acute lymphoblastic leukemia (B-ALL) patients.
Review
Oncology
William G. Wierda, Andrew Rawstron, Florence Cymbalista, Xavier Badoux, Davide Rossi, Jennifer R. Brown, Alexander Egle, Virginia Abello, Eduardo Cervera Ceballos, Yair Herishanu, Stephen P. Mulligan, Carsten U. Niemann, Colin P. Diong, Teoman Soysal, Ritsuro Suzuki, Hoa T. T. Tran, Shang-Ju Wu, Carolyn Owen, Stephan Stilgenbauer, Paolo Ghia, Peter Hillmen
Summary: Assessment of measurable residual disease in chronic lymphocytic leukemia plays a crucial role in evaluating treatment outcomes, with undetectable residual disease status correlating with favorable prognoses. Key issues include standardizing methodology for assessment, determining the timing and tissue for evaluation, and understanding the application in clinical practice versus trials for future research.
Article
Veterinary Sciences
Emily D. Rout, Julia D. Labadie, Janna A. Yoshimoto, Paul R. Avery, Kaitlin M. Curran, Anne C. Avery
Summary: The study aimed to assess the presentation and outcome in dogs with BCLL, evaluating the prognostic relevance of clinical and flow cytometric factors. Results indicated that Boxer dogs and cases with high Ki67 levels had more aggressive disease.
JOURNAL OF VETERINARY INTERNAL MEDICINE
(2021)
Review
Oncology
Giovanni D'Arena, Alessandro Sgambato, Silvestro Volpe, Giuseppe Coppola, Rachele Amodeo, Virginia Tirino, Fiorella D'Auria, Teodora Statuto, Luciana Valvano, Giuseppe Pietrantuono, Silvia Deaglio, Dimitar Efremov, Luca Laurenti, Antonella Aiello
Summary: Measurable residual disease (MRD) is a relevant parameter for assessing the response to therapy in chronic lymphocytic leukemia (CLL). Flow cytometry has emerged as the most useful and standardized approach for measuring and quantifying MRD. The increased sensitivity of MRD measurements has led to improved therapeutic strategies for CLL, making MRD detection more applicable in this context.
HEMATOLOGICAL ONCOLOGY
(2022)
Article
Veterinary Sciences
Elena Celant, Laura Marconato, Damiano Stefanello, Pierangelo Moretti, Luca Aresu, Stefano Comazzi, Valeria Martini
Summary: Phenotypic aberrancies in canine lymphomas were retrospectively studied, and their clinical and clinical pathological features at diagnosis were described. Different aberrant phenotypes were found in different lymphoma subtypes, providing clues for the diagnosis and prognosis of lymphoma.
VETERINARY SCIENCES
(2022)
Article
Oncology
Jennifer A. Woyach
Summary: MRD assessment in chronic lymphocytic leukemia (CLL) may help determine prognosis, but its predictive value varies in different therapeutic contexts. It is unclear whether an MRD-guided treatment strategy is superior to fixed-duration therapy, requiring further research for validation.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Oncology
Wei Wang, Jie Xu, Joseph D. Khoury, Naveen Pemmaraju, Hong Fang, Roberto N. Miranda, C. Cameron Yin, Siba El Hussein, Fuli Jia, Zhenya Tang, Shimin Hu, Marina Konopleva, L. Jeffrey Medeiros, Sa A. Wang
Summary: This study investigated the immunophenotypic and molecular profiles of pDC-AML and BPDCN and found that they have different phenotypes and mutation profiles, indicating that they are two distinct entities.
Article
Hematology
James Nguyen, Cameron Wellard, Eliza Chung, Chan Y. Cheah, Michael Dickinson, Nicole Wong Doo, Colm Keane, Dipti Talaulikar, Leanne Berkahn, Susan Morgan, Nada Hamad, Tara Cochrane, Anna M. Johnston, Cecily Forsyth, Stephen Opat, Allison Barraclough, Howard Mutsando, Sumita Ratnasingam, Pratyush Giri, Erica M. Wood, Zoe K. McQuilten, Eliza A. Hawkes
Summary: This study summarizes the clinical characteristics of 498 Australian patients with classical Hodgkin lymphoma (cHL), including baseline characteristics, histologic subtype, and treatment patterns. Patient demographics and distribution of histopathological subtypes of cHL are consistent with reported international cohorts. The most common therapy for both early and advanced-stage disease is doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), and 48% of patients with early-stage disease received radiotherapy.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Medicine, General & Internal
Jacinta Perram, Duncan Purtill, Ashish Bajel, Jason Butler, Tracey O'Brien, Benjamin Teh, Nicole Gilroy, Phoebe J. Ho, Richard Doocey, Thomas Hills, Travis Perera, Genevieve Douglas, Shanti Ramachandran, Lynette Chee, Judith Trotman, Robert Weinkove, Steven Keogh, Chris Fraser, Tara Cochrane, Anne-Marie Watson, Peter Diamond, Maya Latimer, Ian Irving, Emily Blyth, Chan Cheah, Theresa Cole, Sam Milliken, Hung Yang, Matthew Greenwood, Peter Bardy, Glen Kennedy, Stephen Larsen, Rachel Conyers, Nada Hamad
Summary: Patients undergoing post-haemopoietic stem cell transplant or CAR-T therapy are at a significant risk of morbidity and mortality from COVID-19 due to their weakened immune system. As COVID-19 cases continue to rise in Australia and New Zealand, guidance specifically tailored to local healthcare systems, medication availability, and emerging therapies is crucial to ensure optimal management of these high-risk patients.
INTERNAL MEDICINE JOURNAL
(2023)
Article
Oncology
Catherine Thieblemont, Tycel Phillips, Herve Ghesquieres, Chan Y. Cheah, Michael Roost Clausen, David Cunningham, Young Rok Do, Tatyana Feldman, Robin Gasiorowski, Wojciech Jurczak, Tae Min Kim, David John Lewis, Marjolein van der Poel, Michelle Limei Poon, Mariana Cota Stirner, Nurgul Kilavuz, Christopher Chiu, Menghui Chen, Mariana Sacchi, Brian Elliott, Tahamtan Ahmadi, Martin Hutchings, Pieternella J. Lugtenburg
Summary: Epcoritamab is a subcutaneously administered bispecific antibody that activates T cells to kill malignant B cells. It has shown potent antitumor activity in patients with B-cell non-Hodgkin lymphoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Stephen P. Mulligan, Stephen Opat, Chan Y. Cheah, Bryone Kuss, Mark Hertzberg, Paula Marlton, Sarah Poplar, Andrea Puig, Marija McGeachie, Robert Weinkove, Constantine S. Tam
Summary: This study assessed the duration of treatment for patients accessing ibrutinib through the Named Patient Program and found that it demonstrated consistent efficacy and tolerability, providing clinical benefit for relapsed/refractory CLL/SLL and MCL patients in line with clinical trial results.
LEUKEMIA & LYMPHOMA
(2023)
Article
Surgery
Ryan Cohen, Aaron Beasley, Melanie McCoy, Cameron Platell, Katie Meehan, Elin Gray, Kathy Fuller
Summary: This study reported the outcomes of locally performed postoperative ctDNA testing during routine clinical care and its association with the recurrence of colorectal cancer. The results showed that there were few cases with detectable ctDNA postoperatively, and no adverse association between postoperative ctDNA positivity and colorectal cancer recurrence was observed. This suggests the need for further validation of postoperative ctDNA as a predictive marker for colorectal cancer recurrence.
ANZ JOURNAL OF SURGERY
(2023)
Editorial Material
Hematology
Wendy N. Erber
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Review
Hematology
Zi Yun Ng, Kathryn A. Fuller, Allegra Mazza-Parton, Wendy N. Erber
Summary: Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies. Diagnosis and classification of MPN rely on blood and bone marrow morphology, with key features including architecture, cellularity, cell types, reticulin content, and presence of megakaryocytes. Accurate morphologic diagnosis is crucial due to prognostic differences and varying therapies. Differentiating reactive conditions and MPN can be challenging, especially in triple negative MPN cases.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Review
Hematology
Pooja Ramesh, Henry Y. L. Hui, Leon M. Brownrigg, Kathy A. Fuller, Wendy N. Erber
Summary: Chimeric antigen receptor (CAR) T-cell therapy is a customized immunotherapy for hematological malignancies, using genetically engineered T-cells to recognize and kill tumor cells. CAR T-cells harness the cytotoxic capacity of a patient's immune system and have the potential to generate robust anti-tumor responses.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Letter
Genetics & Heredity
Wendy N. Erber, Henry Y. L. Hui, Thomas I. Mincherton, Matthew Harms, Sarah Clarke, Kathy A. Fuller
JOURNAL OF HUMAN GENETICS
(2023)
Letter
Pathology
Daniel D. Wong, Rodas Amanuel, Yee Jia Chua, Shona Hendry, Peter Robbins, Chan Y. Cheah, Benhur Amanuel
Article
Hematology
Chan Y. Cheah, John F. Seymour
Summary: Marginal zone lymphomas (MZL) are the second most common indolent lymphoma with three recognized subtypes. Diagnosis requires biopsy and identification of clonal B-cell infiltrate with negative CD5 and CD10 immunophenotype. Prognostic models, such as MALT-IPI and MZL-IPI, have been developed. Treatment options include chemo-immunotherapy, radiotherapy, and emerging therapies like BTK inhibitors for relapsed/refractory disease.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Editorial Material
Hematology
Chan Y. Cheah
Summary: This study examines the long-term outcomes of pembrolizumab, an immune checkpoint inhibitor, in patients with relapsed/refractory classic Hodgkin lymphoma (HL).
Article
Hematology
Adrian Minson, Nada Hamad, Pietro Di Ciaccio, Dipti Talaulikar, Matthew Ku, Sumita Ratnasingam, Chan Cheah, Costas K. Yannakou, Mark Bishton, Zi Yun Ng, Shivam Agrawal, Andrew Mcquillan, Anna Johnston, Emily Choong, Kimberly Wong, James Mcquillan, Ashley Beekman, Eliza Hawkes, Michael Dickinson
Summary: This study analyzed the treatment outcomes of 389 patients with mantle cell lymphoma and found that the rate of lymphoma-related death increased after each treatment line. Older age at diagnosis and early relapse after induction therapy were associated with a higher risk of death after second-line treatment. The results of this study support the exploration of novel therapies in earlier treatment lines.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Biochemical Research Methods
Ryan J. Collinson, Darren Boey, Lynne Wilson, Zi Yun Ng, Bob Mirzai, Hun Chuah, Michael F. Leahy, Rebecca Howman, Matthew Linden, Kathy Fuller, Wendy N. Erber, Belinda B. Guo
Summary: Platelets, small circulating fragments of cells, play important roles in various physiological and pathological processes. We have developed a method called PlateletSeq, which allows for the analysis of platelet gene expression using low levels of RNA input without the need for specialist bioinformatic skills. This method has the potential to be applied in biomarker discovery and studying platelet biology in patient samples.
Article
Biochemical Research Methods
Ryan Cohen, Tracey Lee-Pullen, Timothy J. Miller, Katie Meehan, Kathy Fuller, Melanie J. McCoy
Summary: Exploring the tumour microenvironment provides insight into the unique interaction between the host and tumour. Immune biomarkers within the tumour microenvironment in colorectal cancer are more accurate in predicting disease recurrence than traditional histopathological staging. Multiplex immunofluorescence allows for simultaneous assessment of multiple markers to accurately classify immune cells and their spatial relationship to tumour tissue.